✦ LIBER ✦

A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance)

✍ Scribed by Gupta, Pankaj; Mulkey, Flora; Hasserjian, Robert P.; Sanford, Ben L.; Vij, Ravi; Hurd, David D.; Odenike, Olatoyosi M.; Bloomfield, Clara D.; Owzar, Kouros; Stone, Richard M.; Larson, Richard A.

Book ID: 125358923
Publisher: Springer US
Year: 2013
Tongue: English
Weight: 204 KB
Volume: 31
Category: Article
ISSN: 0167-6997
DOI: 10.1007/s10637-013-9978-z

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase 1 study of PTK787/ZK 222584, a sma

Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome

✍ Roboz, G J; Giles, F J; List, A F; Cortes, J E; Carlin, R; Kowalski, M; Bilic, S 📂 Article 📅 2006 🏛 Nature Publishing Group 🌐 English ⚖ 120 KB

A phase I study of the oral vascular end

A phase I study of the oral vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor PTK787/ZK 222584 on a twice daily schedule in patients with advanced cancer

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 143 KB

1474 POSTER A phase I, open-label study

1474 POSTER A phase I, open-label study with escalating doses of intravenous PTK787/ZK 222584, a multi-VEGF receptor inhibitor, followed by multiple oral daily dosing to assess the absolute bioavailability of PTK787/ZK 222584 after single and multiple doses in advanced cancer patients

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 134 KB

35 POSTER A Phase I trial of a combinati

35 POSTER A Phase I trial of a combination of the mToR Inhibitor Everolimus (RAD001) and two schedules of the vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor Vatalanib (PTK787/ZK222584) in patients (pts) with advanced solid tumors

✍ G. Dy; G. Croghan; A. Furth; J. Reid; L. Hanson; M. Roos; A. Tan; A. Adjei 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 134 KB

A Phase II Safety and Efficacy Study of

A Phase II Safety and Efficacy Study of the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Pazopanib in Patients With Metastatic Urothelial Cancer

✍ Pili, Roberto; Qin, Rui; Flynn, P.J.; Picus, Joel; Millward, Michael; Ho, Wing M 📂 Article 📅 2013 🏛 CIG Media Group, LP. 🌐 English ⚖ 791 KB